Table A3.
Subgroup analysis of the effect of prior use of drugs in COVID-19 patients with diabetes mellitus.
| Progression, No. (%) | Improvement/Stabilization, No. (%) | p | |
|---|---|---|---|
| (n = 10) | (n = 11) | Value | |
| Age, median (IQR) | 52.5 (47.0–55.0) | 52.0 (51.0–55.0) | 0.915 |
| Dipeptidyl peptidase-4 inhibitor | 8 (80.0%) | 8 (72.7%) | >0.999 |
| Metformin | 6 (60.0%) | 6 (54.5%) | >0.999 |
| Angiotensin II receptor blocker | 4 (40.0%) | 1 (9.1%) | 0.251 |
| Ibuprofen | 1 (10.0%) | 1 (9.1%) | >0.999 |
| Thiazolidinedione | 1 (10.0%) | 0 (0.0%) | 0.476 |
| Sulfonylurea | 2 (20.0%) | 2 (18.2%) | >0.999 |
| Sodium-glucose cotransporter-2 inhibitor | 0 (0.0%) | 1 (9.1%) | >0.999 |
| Gabapentinoid | 0 (0.0%) | 1 (9.1%) | >0.999 |
| Isosorbide | 1 (10.0%) | 0 (0.0%) | 0.476 |